Two recent deaths at Grifols plasma clinics in Winnipeg have sparked scrutiny of the for-profit plasma donation industry in Canada. Health authorities are investigating the fatalities, which occurred at facilities where donors can give plasma twice weekly for payment. The incidents have raised questions about the safety of frequent plasma donation, a practice that generates $40.35 billion in annual revenue globally.

Plasma donation is widely considered low-risk, with millions donating regularly across North America. However, recent clinical trials found that frequent donors show reduced levels of proteins and antibodies after several months of twice-weekly donations. While the FDA allows donations every two days and the Red Cross limits them to once every four weeks, there's no consensus among regulators about optimal donation intervals. Some Canadian provinces have banned paying for plasma altogether.

The deaths have intensified debate about the ethics of compensating plasma donors, particularly as economic pressures drive more people to seek supplemental income through donation. Canadian Blood Services previously opposed private plasma collection but reversed course in 2022, partnering with Grifols to expand operations. As the investigation continues, the incidents highlight the tension between meeting growing global demand for plasma-derived medicines and ensuring donor safety.